Ketamine Drug Test

This test detects the presence of ketamine and its primary metabolite norketamine in urine. Ketamine is metabolised in the liver, and norketamine is the predominant urinary metabolite. The test provides a qualitative result indicating whether these metabolites are present above the assay cut-off level.

Ketamine is not typically included in standard workplace drug screening panels, requiring a targeted assay for reliable detection.

Ketamine detection is relevant for clinical assessment, substance use monitoring, and forensic evaluations. While ketamine has legitimate medical applications, its recreational use may be associated with urological, cognitive, and psychological effects.

Targeted testing supports accurate identification and helps distinguish medical from non-medical use when clinical context is considered.

Testing may be relevant when ketamine use is suspected, as part of an extended drug screening panel, during treatment monitoring, or in forensic or clinical evaluations. Standard drug panels do not typically include ketamine.

Consult a healthcare professional for guidance on when targeted ketamine screening is appropriate.